ITGAX and infection: In comparison, when MAR-5A3 was administered on day 4 after WNV-NY infection and splenocytes analyzed on day 6, we observed a reduced percentage of CD11b+ (P<0.01) and CD11c+ (P<0.02) cells, and this was associated with decreased expression of CD86 only on CD11c+ cells (Figure 5B, P<0.008).